Literature DB >> 6358171

Safracins, new antitumor antibiotics. III. Biological activity.

Y Ikeda, Y Shimada, K Honjo, T Okumoto, T Munakata.   

Abstract

Safracins A and B have antibacterial activity against Gram-positive and Gram-negative bacteria in vitro but no therapeutic activity in mice infected with Staphylococcus aureus. Safracins A and B induce abnormal morphological changes in Echerichia coli cells. Tests with transplantable mice tumors demonstrate that safracins A and B inhibit the growth of P388 leukemia and IMC carcinoma.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6358171     DOI： 10.7164/antibiotics.36.1290

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  3 in total

1.  Regioselectivity of Pictet-Spengler Cyclization Reactions to Construct the Pentacyclic Frameworks of the Ecteinascidin-Saframycin Class of Tetrahydroisoquinoline Antitumor Antibiotics.

Authors:  Guillaume Vincent; Jonathan W Lane; Robert M Williams
Journal:  Tetrahedron Lett       Date:  2007-05-21       Impact factor: 2.415

Review 2.  Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

Authors:  V H Le; M Inai; R M Williams; T Kan
Journal:  Nat Prod Rep       Date:  2015-02       Impact factor: 13.423

3.  Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.

Authors:  Christopher M Rath; Benjamin Janto; Josh Earl; Azad Ahmed; Fen Z Hu; Luisa Hiller; Meg Dahlgren; Rachael Kreft; Fengan Yu; Jeremy J Wolff; Hye Kyong Kweon; Michael A Christiansen; Kristina Håkansson; Robert M Williams; Garth D Ehrlich; David H Sherman
Journal:  ACS Chem Biol       Date:  2011-09-20       Impact factor: 5.100
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.